Ipsen (OTCMKTS:IPSEY) Lifted to “Moderate Buy” at Royal Bank of Canada

Royal Bank of Canada upgraded shares of Ipsen (OTCMKTS:IPSEY) from a hold rating to a moderate buy rating in a research report sent to investors on Monday morning, Zacks.com reports.

Ipsen Price Performance

Shares of IPSEY opened at $31.77 on Monday. Ipsen has a 12-month low of $26.97 and a 12-month high of $34.06. The firm has a 50-day moving average price of $29.36 and a 200 day moving average price of $30.23.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.